West Pharmaceutical Services, Inc. Website

West Pharmaceutical Services, Inc.

NYSE-WST

Company Overview

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

  • Name

    West Pharmaceutical Services, Inc.

  • CEO

    Eric Green

  • Website

    www.westpharma.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1923

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • West’s top-line growth is likely to be buoyed by secular trends in injectable drugs, especially increasing use of biologic drugs.

  • West is a potential beneficiary of the rapidly growing GLP-1 obesity drug market, which is an injectable drug, although the magnitude of long-term benefit to West is unclear at this time.

  • Due to more stringent regulations and increased use of biologics, customers may be incentivized to switch from standard components to high value products, which improves West’s profit margins.

Bears Say

  • Many of West’s products and services could be insourced by customers, and a reversal of higher outsourcing could occur if customers decide they want more control over the supply chain.

  • West has significant customer concentration, with its 10 largest customers accounting for over 40% of total sales.

  • West has been investing large amounts into automation to improve production efficiency; the outcome of automation efforts is uncertain, and returns on these investments may be subpar.

Source: Morningstar Analysis - Oct 24, 2025

What's happening

Nov 8, 2025 - Dec 10, 2025

West Pharmaceutical Services Inc Faces Mixed Market Sentiment Amidst Earnings Strength

  • West Pharmaceutical Services Inc. experienced a notable decline in stock performance, underperforming the S&P 500 and Health Care sector.
  • Analysts have expressed mixed sentiments about WST's future prospects despite strong quarterly earnings results.
  • The company's significant drop on December 8 highlights ongoing challenges in maintaining investor confidence.

Over the past month, West Pharmaceutical Services Inc. (WST) saw a slight decline of 0.7%. This performance is notably below the S&P 500's gain of 1.9%, resulting in an underperformance of -2.6% relative to this benchmark index. The most significant drop for WST occurred on December 8, when shares fell by 4%. Despite these challenges, analysts maintain a consensus rating of "Moderate Buy" with an average price target set at $343.36.

Earlier in December, there were bullish indicators as Morgan Stanley initiated coverage on WST with an Equalweight rating and established a price target at $285.00; prior to this report, shares closed at $277.25. Additionally, November brought positive news when WST reported Q3 results that exceeded expectations with organic growth reaching 5% overall and an impressive increase of 13.3% from its HPP component business—this segment accounts for nearly half of total operations.

Despite these strong earnings suggesting potential for continued growth into Q4 and beyond, market reactions remained muted following initial optimism surrounding quarterly results; gains were not sustained long-term during subsequent trading days after the announcements were made public. The mixed analyst ratings reflect uncertainty regarding how well WST can navigate competitive pressures while sustaining its growth trajectory amid broader market fluctuations.

Overall, while robust quarterly performance provided temporary boosts to investor sentiment earlier in November and early December, it could not counteract negative momentum leading up to mid-December’s sharp decline in share prices; consequently, West Pharmaceutical Services Inc underperformed the Health Care (XLV) sector by -3.3%.

NYSE:WST